EDITORIAL SECTIONS

Abhishek Rungta is the Founder and CEO of INT. (Indus Net Technologies), a full-stack digital transformation company serving 500+ enterprise clients across 45 countries. He writes on enterprise AI adoption, digital transformation, and long-term business building.

Chang supports the preclinical-to-clinical PKPD translation and human efficacious dose prediction of new biological entities at Boehringer Ingelheim. Dr. Chang obtained his MS and Ph.D. in Pharmaceutical Sciences at the University at Buffalo. Under Dr. Dhaval Shah’s mentorship, Dr. Chang investigated antibody and protein therapeutic disposition in the rat brain using large-poremicrodialysis and developed a translational brain PBPK model for monoclonal antibodies.

Dhaval K Shah is an Associate Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Prior to becoming the faculty Prof. Shah served as a Principle Scientist in the ‘Translational Research-Modeling & Simulation’ group at Pfizer Inc. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics. His lab uses the principles of Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling & Simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineered antibodies, multi-specific proteins, immuno-oncology agents, engineered T cells, and antibody-drug conjugates.

Shengjia Wu is a PhD student in the pharmaceutical sciences at the State University of New York at Buffalo. His research focuses on understanding and modeling the macromolecule distribution in the central nervous system.

Yingyi Li gained her master’s degree of pharmaceutical sciences in University at Buffalo. When Yingyi was a master student, she was working in Dr. Dhaval Shah’s lab and became more experienced in PBPK modeling. Yingyi is currently a scientist in the field of pharmacometrics and translational PK-PD in Enhanced Pharmacodynamics.

Rajesh Kumar is an Assistant Professor of Pharmaceutical Sciences at Kerala University of Health Sciences, India. He has been teaching Diploma, Bachelor, and Doctor of Pharmacy students for several years and is actively involved in research. He has authored more than 19 papers and is a reviewer for Bentham Science Publishers. His research includes applying the principles of pharmaceutical sciences, omics technologies, computational biology, and bioinformatics in the broad areas of cancer research, ethnopharmacology, drug delivery, targeting, and formulations.

Seetha Harilal is an Assistant Professor of Pharmacology at Kerala University of Health Sciences, India. She has several years of experience in teaching Diploma, Bachelor, and Doctor of Pharmacy students and is actively pursuing research. She has authored more than 22 papers and is a manuscript reviewer for Bentham Science Publishers, Frontiers in Public Health, Frontiers in Medicine, and Archives of Medical Research (Elsevier). Her research includes the diverse areas of pharmacology and therapeutics, phytopharmaceuticals, cancer research, neurological disorders, and the application of omics technologies, computational pharmacology, and bioinformatics.

Smriti Sharma Bhatia is an associate professor of chemistry at Miranda House, University of Delhi, India.  Her academic and research interests include Computational chemistry and drug design. Currently, her research group is focused on the design of oral drug formulations for Type 2 diabetes mellitus. She is a popular science communicator.

Barbara works closely with leaders across pharmaceutical, medical devices and solution providers serving healthcare organisations - all of whom are using digital product identities.
Much of her time is spent with product owners and senior leaders in packaging, operations, anti-counterfeit, manufacturing, and with system integrators. She is focused on protecting patient safety at scale, serving leadership with trusted data and improving efficiency through innovative solutions.

Barbara's background spans innovation strategy, partnership development, marketing and commercial roles and cross-functional leadership in highly regulated settings. She is known for her collaborative and pragmatic approach, working alongside teams to explore long-term roadmaps that balance progress with responsibility.

Barbara cares deeply about how healthcare systems evolve without compromising what matters most. She is always open to conversations with leaders who are navigating similar challenges and looking to move forward responsibly.